Atai Life Sciences B.V. SEC Filings

ATAI Life Sciences N.V. – Key details from Form 4

Director Amir H. Kalali filed a Form 4 on 27 June 2025 reporting the grant of a non-derivative stock option covering 103,000 common shares of ATAI Life Sciences N.V. The option was issued on 26 June 2025 with an exercise price of $2.25 per share and will vest on the earlier of (i) the day before ATAI’s next annual meeting or (ii) 26 June 2026. The option expires on 26 June 2035. After the transaction, Kalali holds 103,000 derivative securities directly. No open-market purchases or sales of ATAI shares were reported in this filing.

The filing represents a routine equity incentive award designed to align the director’s long-term interests with shareholders. Because the option is not yet exercised, there is no immediate change to share count or insider ownership of outstanding common shares.

ATAI Life Sciences N.V. (ATAI) – Form 4 insider filing

Director Sabrina Martucci Johnson reported the grant of 103,000 stock options on 26 June 2025. The options carry a strike price of $2.25 and expire on 26 June 2035. Vesting occurs on the earlier of the day before ATAI’s next annual meeting or 26 June 2026. Following this transaction Ms. Johnson beneficially owns 103,000 derivative securities, held directly. No non-derivative share transactions were disclosed.

The filing was signed by attorney-in-fact Ryan Barrett on 27 June 2025. No 10b5-1 trading plan box was checked, and the director remains subject to Section 16 reporting obligations.

ATAI Life Sciences N.V. (ATAI) Form 4 highlights: on June 26, 2025 director John Francis Hoffman was granted a stock option covering 206,000 common shares at an exercise price of $2.25 per share.

The option vests 33% on June 26, 2026; the remaining 67% vests in 24 equal monthly installments, reaching full vesting on June 26, 2028. After the award, Hoffman beneficially owns 206,000 derivative securities; no non-derivative share transactions were reported.

The filing, signed by attorney-in-fact Ryan Barrett on June 27, 2025, reflects routine director compensation and does not disclose any sales or purchases of existing shares.

Form 4 filing overview: ATAI Life Sciences N.V. reported that director Laurent Fischer was granted a new option award on 26 June 2025.

Key details:

• Derivative security: Stock option on ATAI common shares
• Quantity granted: 103,000 options
• Exercise price: $2.25 per share
• Expiration: 26 June 2035
• Vesting: Options vest on the earlier of (i) the day before the company’s next annual meeting or (ii) 26 June 2026.
• Ownership status: Following this transaction, the reporting person beneficially owns 103,000 derivative securities, held directly.

The filing represents a routine equity compensation grant to a non-executive director and does not disclose any purchase or sale of ATAI common shares. No cash consideration was exchanged at grant (price of derivative security recorded as $0), indicating a standard incentive award. The disclosure offers no new information on company operations, earnings, or strategic developments.

Form 4 snapshot – ATAI Life Sciences N.V. (NASDAQ: ATAI)

Director Dr. Scott Braunstein reported the grant of 103,000 non-qualified stock options on 26 Jun 2025 at an exercise price of $2.25 per common share. The options expire on 26 Jun 2035 and will vest in full on the earlier of (i) the day prior to the company’s next annual general meeting or (ii) 26 Jun 2026, providing a 12-month maximum vesting horizon. Following the award, Dr. Braunstein now beneficially owns 103,000 derivative securities; no common shares were bought or sold, and no other transactions were reported.

The filing represents routine director compensation under the company’s equity incentive plan. As the grant is at-the-money (current market price ≈ exercise price) and totals roughly <0.1% of shares outstanding, it has minimal dilution impact. Nonetheless, the award aligns the director’s incentives with long-term shareholder value, signalling continued board engagement.

Form 4 filing overview: On 06/27/2025 ATAI Life Sciences N.V. (symbol: ATAI) reported a change in beneficial ownership by Christian Angermayer, who is both a Director and 10% owner.

Key transaction: On 06/26/2025 the insider received a stock option covering 103,000 common shares at an exercise price of $2.25 per share. The award was coded "A" (grant or award) and is held directly by the reporting person.

Vesting & expiration: The option vests on the earlier of (i) the day before ATAIs next annual shareholder meeting or (ii) 06/26/2026, and it expires on 06/26/2035. No deemed execution date or other conditions were noted.

Post-transaction holdings: Following the grant, Mr. Angermayer beneficially owns 103,000 derivative securities (stock options). Table I shows no non-derivative share acquisitions or dispositions.

Investor take-away: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale, so it carries limited immediate signalling value. The award incrementally increases potential dilution but has no direct impact on ATAIs cash position or current share count.